Examining early biomarkers for Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate biomarkers associated with Alzheimer's disease (AD) in cognitively healthy individuals aged 50 to 80 years, with a focus on early diagnosis. Conducted at Skåne University Hospital in Sweden, the study will enroll up to 600 participants, with a significant portion expected to have preclinical AD. Participants will undergo various assessments, including plasma and CSF analysis, PET scans, and MRI, over a participation period of approximately four years. The study seeks to identify potential screening tools for the general population to detect AD risk early.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 50-80
2. Individuals aged 50-60 require at least one of the following risk factors for AD:

   1. Known apolipoprotein E (APOE) -ε4 carrier
   2. Known 1st degree family history of dementia or severe memory loss with onset prior to 75.
   3. Known amyloid brain pathology by either CSF or PET scan.
3. Mini-Mental State Examination (MMSE) ≥26 (aged \>65); MMSE ≥27 (aged 50-65).
4. Score of 12 or above on the Montreal Cognitive Assessment (MoCA) telephone version.
5. Speaks and understands Swedish to the extent that an interpreter is not necessary to fully understand the study information and cognitive tests.

6a. Preclinical Alzheimer's disease subgroup (n=450): Amyloid pathology according to cerebrospinal fluid Alzheimer's disease and amyloid PET scans.

6b. Non-Preclinical Alzheimer's disease subgroup (n=150): No sign of preclinical Alzheimer's disease using cerebrospinal fluid Alzheimer's disease biomarkers or Aβ-PET scans.

Exclusion Criteria:

1. Fulfils the criteria for minor or major neurocognitive disorder according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
2. History of significant brain injury or other known neurologic disease or insult, resulting in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease.
3. Major depression, bipolar disorder, or recurrent psychotic disorders within the past year.
4. History of alcohol and/or substance abuse or dependence within the past year.
5. Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.
6. Refusing or unable to complete baseline cognitive and biomarker assessments (i.e., cognitive testing, blood draw, MRI and PET).

Where it's running

• Skåne University Hospital
  Malmö, Sweden Recruiting

Study contacts

• Principal investigator: Erik Stomrud, MD, PhD — Skane University Hospital and Lund University
• Study coordinator: Erik Stomrud, MD, PhD
• Email: erik.stomrud@med.lu.se
• Phone: +46 40 33 10 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating new blood tests for diagnosing memory disorders

  This study is testing new blood tests to see if they can help diagnose memory disorders like mild dementia and Alzheimer's better than the current method that uses spinal fluid.

  Recruiting Skane University Hospital · Malmö · NCT06122415

• Improving early diagnosis of dementia in primary care

  This study is trying to find better ways to diagnose Alzheimer's and other memory problems early in people visiting their primary care doctors.

  Recruiting Skane University Hospital · Malmö · NCT06120361

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease

  A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.

  Recruiting IRCCS San Raffaele · Milan, Milano · NCT07717567

• Music for Pain and Dementia: Group Drumming for people with early dementia and their caregivers

  This study tests whether group drumming can reduce pain and change brain activity in people with mild dementia or mild cognitive impairment and in their caregivers.

  Recruiting Yale University · New Haven, Connecticut · NCT07602283

• Dementia-friendly pharmacies as a mental health resource for older adults

  This project tests whether pharmacies with memory-test stations can find early cognitive problems in people 60 and older and connect them to follow-up care and support.

  Recruiting Ludwig-Maximilians - University of Munich · Munich, Bavaria · NCT07504965

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.